Yes, multiple sclerosis (MS) causes nerve damage, and it does so through two distinct processes: destroying the protective coating around nerve fibers and, over time, killing the nerve fibers themselves. The first type of damage is sometimes reversible. The second is permanent. Understanding how each happens helps explain why MS symptoms can come and go early on but become lasting as the disease progresses.
How MS Attacks Nerve Fibers
MS is an autoimmune disease, meaning the immune system mistakenly targets the body’s own tissue. In MS, immune cells called T cells launch a chronic inflammatory response against proteins in the myelin sheath, the insulating layer that wraps around nerve fibers in the brain and spinal cord. Think of myelin like the plastic coating on an electrical wire. It keeps signals moving quickly and efficiently.
When T cells, along with other immune cells like macrophages, infiltrate the central nervous system, they release enzymes that break down myelin proteins. This process, called demyelination, strips sections of nerve fibers bare. Without that insulation, electrical signals slow down, travel erratically, or stop altogether. This is what produces the wide range of MS symptoms, from numbness and vision problems to muscle weakness and difficulty walking.
Demyelination alone doesn’t always cause permanent damage. The body has some capacity to rebuild myelin, especially early in the disease. That’s why many people experience relapses (flare-ups of symptoms) followed by periods of partial or full recovery.
When Damage Becomes Permanent
The more serious concern in MS is what happens to the nerve fibers underneath the myelin. Once a nerve fiber is stripped of its coating, it has to work much harder to transmit signals. Normally, electrical impulses jump between small gaps along the fiber. After demyelination, the fiber redistributes its signaling channels across its entire exposed length, which demands far more energy.
This energy crisis sets off a chain reaction. The fiber can’t produce enough fuel to keep up with demand, so calcium builds up inside the cell. Excess calcium activates destructive enzymes, damages the fiber’s internal transport system, and impairs its energy-producing structures. Eventually, the fiber dies. This process, called axonal loss, is irreversible. Once a nerve fiber is gone, it cannot regenerate.
A related process called Wallerian degeneration also contributes. When a nerve fiber is damaged at one point, the entire segment beyond the injury site breaks down. This means a single lesion can cause damage that extends well beyond its visible borders on a brain scan.
Where Nerve Damage Typically Occurs
MS can strike anywhere in the central nervous system, but certain areas are hit more often than others. The spinal cord and optic nerves are particularly common targets. In studies tracking MS relapses, roughly 32% of attacks affected the spinal cord and 27% affected the optic nerve, while only about 10% were isolated to the brain’s cerebral cortex. Brainstem attacks accounted for around 9% and tended to occur in younger patients, with an average age of about 30.
Each location produces different symptoms. Spinal cord damage typically causes sensory problems (numbness, tingling, burning) and motor issues (weakness, stiffness, difficulty walking). Optic nerve damage causes vision loss, often in one eye at a time. Brainstem damage can affect balance, swallowing, and facial sensation. Brain lesions may cause cognitive difficulties, fatigue, or mood changes.
How the Disease Changes Over Time
Most people with MS, roughly 85%, start with a relapsing-remitting course. Symptoms flare up during attacks, then partially or fully resolve during remission. During this phase, the damage is primarily driven by inflammation: immune cells from outside the brain and spinal cord cross into the central nervous system and create discrete patches of demyelination.
Over years or decades, many of these patients transition into a phase called secondary progressive MS. The shift is gradual. Relapses become less frequent, but disability steadily worsens without clear attacks. The underlying mechanism changes too. Instead of waves of immune cells flooding in from the bloodstream, the damage is increasingly driven by immune activity already trapped within the central nervous system, particularly activated microglia (the brain’s resident immune cells). Inflammation doesn’t disappear, but it becomes more diffuse and harder to treat.
Neuroaxonal loss, the permanent death of nerve fibers, is considered the primary driver of irreversible disability in this progressive phase. This is why someone with progressive MS may steadily lose function even when MRI scans show no new inflammatory lesions.
How Nerve Damage Shows Up on MRI
MRI scans are the primary tool for tracking nerve damage in MS. Different scan types reveal different things. Standard scans show bright white spots where active inflammation and demyelination are occurring. These lesions may shrink or disappear as inflammation subsides.
A more telling finding is what radiologists call “T1 black holes.” These dark spots on a specific type of MRI represent areas where tissue has been permanently destroyed, not just inflamed. Some black holes that appear during an acute attack resolve over time as swelling goes down. But black holes that persist, especially those preceded by prolonged periods of active inflammation visible on multiple monthly scans, are more likely to reflect genuine axonal loss rather than temporary swelling.
The 2024 revision of the McDonald diagnostic criteria, the standard framework for diagnosing MS, now recognizes five anatomical locations in the central nervous system where damage can be documented. The optic nerve was newly added as one of these sites. The updated criteria also incorporate newer MRI markers, including the central vein sign and paramagnetic rim lesions, which help distinguish MS lesions from damage caused by other conditions.
Recovery After an Attack
The potential for recovery depends heavily on what type of damage occurred. When demyelination is the main issue, significant recovery is possible. Optic neuritis, inflammation of the optic nerve, is one of the best-studied examples. About 90% of patients recover near-normal visual sharpness within six months, with improvement typically beginning within two to three weeks. After five years, only about 3% of patients have severely impaired vision in the affected eye. However, even patients who recover well often retain subtle deficits in contrast sensitivity or color perception.
Spinal cord attacks follow a less predictable pattern. Some people recover fully from numbness or weakness; others are left with lasting deficits. In general, the earlier in the disease course an attack occurs and the more quickly treatment begins, the better the odds of meaningful recovery.
What doesn’t recover is the nerve fiber itself once it has died. The accumulated loss of nerve fibers over many relapses, or through the slow-burn damage of progressive disease, is what drives long-term disability. Clinicians track this using a standardized disability scale that ranges from 0 (normal neurological exam) to 10. Scores up to 5 describe people who can walk without assistance, with disability determined mainly by how individual body systems are affected. Above 5, walking ability becomes the primary measure, progressing through needing a cane, using a wheelchair, and eventually being bedbound.
Can Damaged Myelin Be Repaired?
Current MS treatments focus on reducing inflammation and preventing new attacks, but they don’t repair damage that has already occurred. That’s why remyelination, restoring the protective coating on nerve fibers, is one of the most actively pursued goals in MS research.
Phase II clinical trials have demonstrated that remyelination is feasible in people with MS, though results so far have been less dramatic than researchers hoped. As of mid-2025, several trials are actively testing different approaches. The most advanced involve clemastine, an antihistamine that appears to stimulate the cells responsible for building new myelin. Multiple clemastine trials are underway, including a Phase III study expected to complete in late 2027. Other compounds being tested include bazedoxifene (a hormone-related drug), metformin (a diabetes medication that may activate repair pathways), and testosterone in men with MS who have low hormone levels.
Some earlier candidates have failed. A drug called opicinumab, which targeted a protein that blocks myelin repair, did not show significant benefit in its major trial and was terminated. Researchers now believe that successful repair will likely require combination approaches: stimulating new myelin production while also protecting surviving nerve fibers and calming the inflammatory environment that prevents repair from taking hold.
Over 1.8 million people worldwide live with MS, most of them diagnosed as young to middle-aged adults. For now, the practical reality is that preserving nerve fibers through early and effective treatment remains the most important strategy, because damage prevented is still far easier to achieve than damage reversed.